Changes of midazolam pharmacokinetics in Wistar rats treated with lipopolysaccharide: Relationship between total CYP and CYP3A2

Innate Immunity

Volumn 14, Issue 5, 2008, Pages 291-297

  Kato, Ryuji ^a   Yamashita, Satoshi ^a   Moriguchi, Jun ^a   Nakagawa, Machiko ^a   Tsukura, Yuri ^a   Uchida, Kagehiro ^b   Amano, Fumio ^a   Hirotani, Yoshihiko ^c   Ijiri, Yoshio ^a   Tanaka, Kazuhiko ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Biomarker Science Co Ltd   (Japan)

^c OSAKA OHTANI UNIVERSITY   (Japan)

Author keywords

CYP2C11; CYP3A2; Lipopolysaccharide; Liver; Midazolam; Total CYP

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CLONAZEPAM; CYTOCHROME P450; CYTOCHROME P450 2C11; CYTOCHROME P450 3A2; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MIDAZOLAM; NITRATE; NITRITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG METABOLISM; ENDOTOXEMIA; ENZYME ACTIVITY; LIVER FUNCTION; MALE; NONHUMAN; PROTEIN LOCALIZATION; RAT; TISSUE DISTRIBUTION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; LIVER; MALE; MEMBRANE PROTEINS; MIDAZOLAM; NITRIC OXIDE; RATS; RATS, WISTAR; STEROID 16-ALPHA-HYDROXYLASE; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS; RATTUS NORVEGICUS;

EID: 61349084901     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425908095956     Document Type: Article

References (15)

1. Hotchkiss RS, Karl IE The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-150.
2. Saitoh T., Kokue E., Shimoda M. The impact of acute phase response on the plasma clearance of antipyrine, theophylline and nifedipine in rabbits. J Vet Pharmacol Ther 2000; 23: 153-158.
3. Lee CC, Lin NT, Hsu YH et al. Inducible nitric oxide synthase inhibition potentiates multiple organ dysfunction induced by endotoxin in conscious rats. J Cardiovasc Pharmacol 2005; 45: 396-403.
4. Wheeler AP, Bernard GR Treating patients with severe sepsis. N Engl J Med 1999; 340: 207-214.
5. Kitaichi K., Li W., Takagi K. et al. Decreased antipyrine clearance following endotoxin administration: In vivo evidence of the role of nitric oxide. Antimicrob Agents Chemother 1999; 43: 2697-2701.
6. Kitaichi K., Nakayama H., Ueyama J. et al. Down-regulation of cytochrome P450 proteins and its activities by Shiga-like toxin II from Escherichia coli O157:H7. Biochem Pharmacol 2004; 67: 1427-1435.
7. Takemura S., Minamiyama Y., Imaoka S. et al. Hepatic cytochrome P450 is directed inactivated by nitric oxide, not by inflammatory cytokines, in the early phase of endotoxemia. J Hepatol 1999; 30: 1035-1044.
8. Moriguchi J., Kato R., Nakagawa M. et al. Effects of lipopolysaccharide on intestinal P-glycoprotein expression and activity. Eur J Pharmacol 2007; 565: 220-224.
9. Kato R., Fujiwara A., Kawai T. et al. Changes in digoxin pharmacokinetics treated with lipopolysaccharide in Wistar rats. Biol Pharm Bull 2008; 31:.
10. Kato R., Tokunaga Y., Kawai T. et al. Effects of CpG-DNA from Escherichia coli on digoxin pharmacokinetics. Biol Pharm Bull 2008; In press.
11. Chin BE, Thierry B., Gianni C. et al. Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CTP3A activity. Eur J Clin Pharmacol 2004; 60: 237-246.
12. Eeckhoudt SL, Horsmans Y., Verbeeck RK Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica 2002; 32: 975-984.
13. Higashikawa F., Murakami T., Kaneda T. et al. In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats. J Pharm Pharmacol 1999; 51: 405-410.
14. Bittner B., Gonzalez RC, Isel H. et al. Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. Eur J Pharm Biopharm 2003; 56: 143-146.
15. Fujishima S., Akikawa N. Pathophysiolosy of hypercytokinemia. Nippon Rinsho 2004; 62: 2004-2012.